Zobrazeno 1 - 10
of 261
pro vyhledávání: '"antibody–drug conjugates (ADCs)"'
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundAntibody-drug conjugates (ADCs) have emerged as the focus and hotspots in the cancer field, yet the accompanying ocular toxicity has often been underestimated. We aimed to comprehensively and comparatively analyze the risk of ocular toxicit
Externí odkaz:
https://doaj.org/article/23952e97d1da4e059ed64b03b7adeff1
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background: Antibody-drug conjugates (ADCs) are a relatively new class of anticancer agents that use monoclonal antibodies to specifically recognize tumour cell surface antigens. However, off-target effects may lead to severe adverse events. This stu
Externí odkaz:
https://doaj.org/article/a7fda807287648b3b5e3adfa1b5542d7
Publikováno v:
Pharmaceutics, Vol 16, Iss 2, p 221 (2024)
Antibody–drug conjugate (ADC) therapy, an advanced therapeutic technology comprising antibodies, chemical linkers, and cytotoxic payloads, addresses the limitations of traditional chemotherapy. This study explores key elements of ADC therapy, focus
Externí odkaz:
https://doaj.org/article/8dbf5054e87a44d8a57179ba20e8ee44
Autor:
Yixiang ZHU, Zhijie WANG
Publikováno v:
Chinese Journal of Lung Cancer, Vol 25, Iss 7, Pp 468-476 (2022)
Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers,
Externí odkaz:
https://doaj.org/article/d54e7b7f0e834b6b97f843bf5702dc46
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
OncoTargets and Therapy, Vol Volume 15, Pp 331-343 (2022)
Xiwu Hui,1,* Can Yuan,1,* Weirong Cao,1 Wenli Ge,1 Di Zhang,1 Mo Dan,2 Qian Zhao,2 Boning Liu,1,* Bing Yao1,* 1Institute of Quality Analysis, CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang, Hebei, People’s Republic of China
Externí odkaz:
https://doaj.org/article/de109a2d1c564706a5e14afa16ec6448
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 13, p 11011 (2023)
Antibody—drug conjugates (ADCs) play important roles in tumor therapy. However, traditional ADCs are limited by the extremely large molecular weight of the antibody molecules, which results in low permeability into solid tumors. The use of small AD
Externí odkaz:
https://doaj.org/article/caa93de2816b4cd38f9717cfb8f1cc8c
Autor:
Marloes A. Wijdeven, Remon van Geel, Jorin H. Hoogenboom, Jorge M. M. Verkade, Brian M. G. Janssen, Inge Hurkmans, Laureen de Bever, Sander S. van Berkel, Floris L. van Delft
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Antibody-drug conjugates (ADCs) are increasingly powerful medicines for targeted cancer therapy. Inspired by the trend to further improve their therapeutic index by generation of homogenous ADCs, we report here how the clinical-stage GlycoConnect™
Externí odkaz:
https://doaj.org/article/848d309b246a42aca0115d74462db631
Autor:
Benjamina Esapa, Jiexuan Jiang, Anthony Cheung, Alicia Chenoweth, David E. Thurston, Sophia N. Karagiannis
Publikováno v:
Cancers, Vol 15, Iss 6, p 1845 (2023)
Antibody drug conjugates (ADCs) are powerful anti-cancer therapies comprising an antibody joined to a cytotoxic payload through a chemical linker. ADCs exploit the specificity of antibodies for their target antigens, combined with the potency of cyto
Externí odkaz:
https://doaj.org/article/8b0428dca16b406fabac4a0dc1f46535